Clinical trial • Phase I • Oncology

ORIC-944 for Prostate cancer | Metastatic prostate cancer

Phase I trial of ORIC-944 for Prostate cancer | Metastatic prostate cancer. 202 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Prostate cancer | Metastatic prostate cancer
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
21-10-2024
First CTIS Authorization Date
03-02-2025

Trial design

Phase I trial across 3 sites in Spain.

Target Sample Size
202

Eligibility

Recruits 202 No vulnerable populations selected..

Vulnerable Population
No vulnerable populations selected.

Recruitment

Planned Sample Size
202
Recruitment Window Months
37

Geography

Total Number Of Sites
3
Total Number Of Participants
202

Spain

Earliest CTIS Part Ii Submission Date
27-01-2025
Latest Decision Or Authorization Date
28-04-2026
Processing Time Days
456
Number Of Sites
3
Number Of Participants
48

Sites

Site Name
Hospital Universitario Quironsalud Madrid
Department Name
NEXT Madrid - Oncology
Contact Person Name
Valentina Boni
Contact Person Email
vboni@nextoncology.eu
Site Name
Hospital Universitari Vall D Hebron
Department Name
Medical Oncology Department
Contact Person Name
Joaquin Mateo Valderrama
Contact Person Email
jmateo@vhio.net
Site Name
Hospital Quironsalud Barcelona
Department Name
Medical Oncology
Contact Person Name
Fabricio Racca
Contact Person Email
fraca@nextoncology.eu

Sponsor

Primary sponsor

Full Name
ORIC Pharmaceuticals Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
ORIC-944

Related trials

Other published trials that may interest you.